The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    Lilly and Johnson & Johnson on Monday added to a run of private company acquisitions that has accounted for the majority of the sector’s dealmaking activity in 2026.

    Updated Nov. 16, 2026
  • Workers in white cleanroom suits stand in a futuristic corridor beside a rolling cart with two monitors, surrounded by reflective metallic panels in a bright sterile setting.
    Image attribution tooltip
    Gremlin via Getty Images
    Image attribution tooltip
    Sponsored by Nebius

    The infrastructure decisions that will enable tomorrow’s biggest breakthroughs

    Faster drug discovery depends on more than the model. What drug developers need to know about AI.

  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    Roche breast cancer pill cleared by FDA

    Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.

    Updated 21 hours ago
    FDA
  • The staff of CG Oncology rings the opening bell at Nasdaq as confetti falls.
    Image attribution tooltip
    Permission granted by Nasdaq, Inc.
    Image attribution tooltip

    CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

    CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares. 

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly adds to buyout streak with $1.5B purchase of startup Calytrix

    Lilly’s 15th announced acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.

  • Johnson & Johnson's pharmaceutical office in Madrid, Spain.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    J&J bets $2.2B on Ollin’s vision loss drug

    The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.

  • Illustration of lung cancer
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

    The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval. 

    FDA
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: Brain drugs are back on venture capitalists’ minds

    Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.

  • A group of investors at Sofinnova Partners.
    Image attribution tooltip
    Permission granted by Sofinnova Partners
    Image attribution tooltip
    Emerging biotech

    One of Europe’s leading VCs banks a €725M ‘crossover’ fund

    Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.

  • Picture of a Belharra wave in the ocean.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Big-name investors pour $100M into DNA therapeutics developer Seawolf

    The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    At least four neuroscience-focused biotechs have raised venture fundings since late October, matching the total number of rounds raised by brain drug developers over the previous six months, according to BioPharma Dive data.

    Updated Nov. 12, 2026
  • Nasdaq signage at Broadway and West 44th Street in New York City's Times Square.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Windward prices $175M IPO to advance China-licensed lung drugs

    The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties

    Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.

  • A horizontal photo depicting the top of the U.S. Capitol set against a blue sky.
    Image attribution tooltip
    Tom Brenner/Getty Images via Getty Images
    Image attribution tooltip
    China competition

    BIO unveils plan for US to remain biotech’s ‘global leader’

    A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.

  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Blackstone bets $1.5B on Pfizer’s obesity drug

    The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.

  • A white building entrance sign reads "Bristol Myers Squibb," with a barbed fence behind it surrounded by flowers.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Bristol Myers research chief to depart in ‘evolution’ of company’s structure

    Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies. 

  • A picture of buildings in Berlin.
    Image attribution tooltip
    Sean Gallup / Staff via Getty Images
    Image attribution tooltip

    Drug price hikes in Germany could push US costs higher, study says

    The report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.

  • An illustration of vacancies for job openings.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    The FDA has over 1k open jobs — and the staffing shortage is hitting pharma

    The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.

    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning

    The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.

  • Futuristic 3D cubes showing DNA base pairs and a double helix.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Gene editing

    Beam’s base editing therapy for sickle cell hits goal in pivotal trial

    The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.

  • A person points to the start of a successful business on a blue stock market graph.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    PepGen soars on promising early data for muscular dystrophy drug

    While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics. 

  • Vivek Ramaswamy embraces a woman onstage at an Ohio Republican election-night event in Columbus, Ohio.
    Image attribution tooltip
    Jon Cherry via Getty Images
    Image attribution tooltip
    Trump administration

    Ramaswamy’s biotech baggage haunted his political run

    A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.

  • An illustration of beta amyloid plaques and tau in the brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Brain drug revival

    London biotech Oyster harvests $60M for tau-targeting brain drugs

    Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Rezera and Windward Bio are set to go public Wednesday and Thursday, respectively, in a pair of offerings that could each pull in more than $200 million.

    Updated Nov. 11, 2026
  • Bayer
    Image attribution tooltip
    Permission granted by Bayer
    Image attribution tooltip

    Bayer wins FDA nod for a new kind of blood thinner

    Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention. 

    FDA
  • A 3D illustration of a DNA double helix
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis reveals cancer cases possibly linked to gene therapy Zolgensma

    The FDA is now investigating the risk of malignancy associated with Zolgensma and is “evaluating whether regulatory action is appropriate.”

    Updated Nov. 9, 2026